Potential utility of natural products as regulators of breast cancer-associated aromatase promoters

Reproductive Biology and Endocrinology

Volumn 9, Issue , 2011, Pages

  Khan, Shabana I ^a,b   Zhao, Jianping ^a   Khan, Ikhlas A ^a,b   Walker, Larry A ^a,b   Dasmahapatra, Asok K ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(1,3 BENZOTHIAZOL 2 YL)[2 [2 (3 PYRIDINYL)ETHYLAMINO] 4 PYRIMIDINYL]ACETONITRILE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AROMATASE; AROMATASE INHIBITOR; BEXAROTENE; BIOCHANIN A; CELL NUCLEUS RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; GLUCOCORTICOID RECEPTOR; GRAPE SEED EXTRACT; ISOLIQUIRITIGENIN; MESSENGER RNA; PIOGLITAZONE; RESVERATROL; ROSIGLITAZONE; TROGLITAZONE; BIOLOGICAL PRODUCT; PHYTOESTROGEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CHEMOPROPHYLAXIS; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFICACY; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN SYNTHESIS; GENE EXPRESSION; HUMAN; NONHUMAN; OSTEOLYSIS; POSTMENOPAUSE; REVIEW; BIOSYNTHESIS; BREAST TUMOR; DRUG EFFECT; FEMALE; METABOLISM; NEOPLASM; PREGNANCY; PROMOTER REGION;

VITACEAE;

AROMATASE; AROMATASE INHIBITORS; BIOLOGICAL AGENTS; BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PHYTOESTROGENS; PREGNANCY; PROMOTER REGIONS, GENETIC;

EID: 79959189104     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-9-91     Document Type: Review

References (120)

1. Simpson ER. Aromatase: biologic relevance of tissue specific expression. Semin Reprod Med 2004, 22:11-23.
2. Means GD, Mahendroo MS, Corbin CJ, Mathis JM, Powell FE, Mendelson CR, Simpson ER. Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J Biol Chem 1989, 264:19385-19391.
3. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Transcriptional regulation of CYP 19 gene (aromatase) expression in adipose stromal cells in primary culture. J Steroid Biochem Mol Biol 1997, 61:203-210. 10.1016/S0960-0760(97)80013-1, 9365191.
4. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M. Aromatase-a brief overview. Annu Rev Physiol 2002, 64:93-127. 10.1146/annurev.physiol.64.081601.142703, 11826265.
5. Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 2009, 457(7226):219-223. 10.1038/nature07614, 2820300, 19129847.
6. Milani M, Jha G, Potter DA. Anastrozole use in early stage breast cancer of post-menopausal women. Clin Med Ther 2009, 1:141-156. 2753667, 19794821.
7. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003, 348(24):2431-2442. 10.1056/NEJMra023246, 12802030.
8. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003, 86(3-5):225-230. 10.1016/S0960-0760(03)00360-1, 14623515.
9. Czajka-Oraniec I, Simpson ER. Aromatase research and its clinical significance. Endokrynol Pol 2010, 61:126-134.
10. Harada N, Yamada K, Saito K, Kibe N, Dohmae S, Takagi Y. Structural characterization of the human estrogen synthetase (aromatase) gene. Biochem Biophys Res Commun 1990, 166:365-372. 10.1016/0006-291X(90)91954-Q, 2302210.
11. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6:1-42. 10.1097/00008571-199602000-00002, 8845856.
12. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B, Tamura M, Langoi D, Deb S. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005, 57:359-383. 10.1124/pr.57.3.6, 16109840.
13. Bulun SE, Simpson ER. Aromatase expression in women's cancer. Adv Exp Med Biol 2008, 630:112-132. 10.1007/978-0-387-78818-0_8, 18637488.
14. Chen D, Reierstad S, Lu M, Lin Z, Ishikawa H, Bulun SE. Regulation of breast cancer-associated aromatase promoters. Cancer Lett 2009, (273):15-27.
15. Jiao J, Xiang H, Liao Q. Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer. Curr Med Chem 2010, 17:3476-3487. 10.2174/092986710792927877, 20738251.
16. Mahendroo MS, Means GD, Mendelson CR, Simpson ER. Tissue-specific expression of human P-450AROM. The promoter responsible for expression in adipose tissue is different from that utilized in placenta. J Biol Chem 1991, 266:11276-11281.
17. Simpson ER, Michael MD, Agarwal VR, Hinshelwood MM, Bulun SE, Zhao Y. Expression of the CYP19 (aromatase) gene: an unsual case of alternative promoter usage. FASEB J 1997, 11:29-36.
18. Sebastian S, Takayama K, Shozu M, Bulun SE. Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is up-regulated in breast cancer tissue. Mol Endocrinol 2002, 16:2243-2254. 10.1210/me.2002-0123, 12351690.
19. Bulun SE, Takayama K, Suzuki T, Sasano H, Yilmaz B, Sebastian S. Organization of the human aromatase p450 (CYP19) gene. Semin Reprod Med 2004, (22):5-9.
20. Zhao Y, Mendelson CR, Simpson ER. Characterization of the sequences of human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stomal cells and fetal hepatocytes. Mol Endocrinol 1995, 9:340-349. 10.1210/me.9.3.340, 7776980.
21. Zhao Y, Nichols JE, Bulun SE, Mendelson CR, Simpson ER. Aromatase p450 gene expression in human adipose tissue. Role of Jak/STAT pathway in regulation of the adipose-specific promoter. J Biol chem 1995, 270:16449-16457. 10.1074/jbc.270.27.16449, 7608217.
22. Bulun SE, Lin Z, Zhao H, Lu M, Amin S, Reierstad S, Chen D. Regulation of aromatase expression in breast cancer tissue. Ann NY Acad Sci 2009, 1155:121-131. 10.1111/j.1749-6632.2009.03705.x, 19250199.
23. Zhou J, Gurates B, Yang S, Sebastian S, Bulun SE. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Res 2001, 61:2328-2334.
24. Utsumi T, Harada N, Maruta M, Takagi Y. Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. J Clin Endocrinol Metab 1996, 81:2344-2349. 10.1210/jc.81.6.2344, 8964875.
25. Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 1996, 81:3843-3849. 10.1210/jc.81.11.3843, 8923826.
26. American Cancer Society Cancer statistics. 2006, American Cancer Society., http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/index
27. IARC (International Agency of Research on Cancer) Overall evaluation of Carcinogenicity: An updating of IARC Monographs Volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl 1987, 7:272-310. IARC (International Agency of Research on Cancer).
28. IARC (International Agency for Research on Cancer) Hormonal concentration and postmenopausal hormone therapy. IARC Monogr Eval Carcinog Risks Hum 1999, 72:474-530. IARC (International Agency for Research on Cancer).
29. Cavalieri E, chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 2006, 1766:63-78.
30. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354:270-282. 10.1056/NEJMra050776, 16421368.
31. Longcope C, Pratt JH, Schneider SH, Fineberg SE. Aromatization of androgens by muscle and adipose tissue in vivo. J Clin Endocrinol Metab 1978, 46:146-152. 10.1210/jcem-46-1-146, 752017.
32. Sasano H, Uzuki M, Sawai T, Nagura H, Matsunaga G, Kashimoto O, Harada N. Aromatase in human bone tissue. J Bone Miner Res 1997, 12:1416-1423. 10.1359/jbmr.1997.12.9.1416, 9286757.
33. Subramanian A, Salhab M, Mokbel K. Oestrogen producing enzymes and mammary carcinogenesis: a review. Breast Cancer Res Treat 2008, 111:191-202. 10.1007/s10549-007-9788-0, 17934808.
34. Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H, Takagi Y. Localized expression of aromatase in human vascular tissues. Cir Res 1999, 84:1285-1291.
35. Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 2001, 142:4589-4594. 10.1210/en.142.11.4589, 11606422.
36. Castagnetta LA, Lo Casto M, Granata OM, Polito L, Calabro M, Lo Bue A, Bellavia V, Carruba G. Estrogen content and metabolism in human breast tumor tissues and cells. Ann NY Acad Sci 1996, 784:314-324. 10.1111/j.1749-6632.1996.tb16246.x, 8651580.
37. Miki Y, Suzuki T, Sasano H. Controversies of aromatase localization in human breast cancer-stromal versus parenchymal cells. J Steroid Biochem Mol Biol 1990, 37:1055-1059. 10.1016/0960-0760(90)90465-W, 2285581.
38. Suzuki T, Miki Y, Akahira J-I, Moriya T, Ohuchi N, Sasano H. Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations. Endocrine J 2008, 55:455-463.
39. Miller WR, Anderson TJ, Jack WJ. Relationship between tumor aromatase acitivity, tumor characteristics and response to therapy. J steroid Biochem Mol Biol 1990, 37:1055-1059. 10.1016/0960-0760(90)90465-W, 2285581.
40. Suzuki T, Moriya T, Ishida T, Ohuchi N, Sasano H. Intracrine mechanism of estrogen synthesis in breast cancer. Biomed Pharmacother 2003, 57:460-462. 10.1016/j.biopha.2003.09.007, 14637389.
41. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and projesteron receptors reconsidered: experience with 5,993 breast cancers. Am J Clin pathol 2005, 123:21-27. 10.1309/4WV79N2GHJ3X1841, 15762276.
42. Wang T, You Q, Huang FS, Xiang H. Recent advances in selective estrogen receptor modulators for breast cancer. Mini Rev Med Chem 2009, 9:1191-1201. 10.2174/138955709789055207, 19817711.
43. Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005, 26:331-345. 10.1210/er.2004-0015, 15814851.
44. Nabholtz JM. Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther Clin Risk Manag 2008, 4:189-204. 2503653, 18728707.
45. Edwards BJ, Raisch DW, Shankaran V, McKoy JM, Gradishar W, Bunta AD, Samaras AT, Boyle SN, Bennett CL, West DP, Guise TA. Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin cancer Res 2011, 17:560-568. 10.1158/1078-0432.CCR-10-1595, 21288927.
46. Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 2010, 123:877-884. 10.1016/j.amjmed.2010.02.028, 20920685.
47. Murata Y, Ogawa Y, Saibara T, Nishioka A, Fujiwara Y, Fukumoto M, Inomata T, Enzan H, Onishi S, Yoshida S. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 2000, 7:1299-1304.
48. Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC. Tamoxifen-associated steatohepatitis report of three cases. J Hepatol 1995, 23:95-97. 10.1016/0168-8278(95)80316-5, 8530816.
49. Oien KA, Moffat D, Curry GW, Dickson J, Habeshaw T, Mills PR, MacSween RN. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999, 353:36-37. 10.1016/S0140-6736(05)74872-8, 10023952.
50. Simpson E, Davis S. Why do the clinical sequelae of estrogen deficiency affect women more than men?. J Clin Endocrinol Metab 1998, 83:2214. 10.1210/jc.83.6.2214, 9626163.
51. Simpson E, Rubin G, Clyne C, Robertson K, Donnell L, Jones M, Davis S. The role of local estrogen biosynthesis in the males and females. Trends Endocrinol Metab 2000, 11:184-188. 10.1016/S1043-2760(00)00254-X, 10856920.
52. Safi R, Kovacic A, Gaillard S, Mutara ER, Simpson ER, McDonnell DP, Clyne CD. Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1 aplha on aromatase promoter II and its inhibition by activated retinoid × receptor suggest a novel target for breast-specific antiestrogen therapy. Cancer Res 2005, 65:11762-11770. 10.1158/0008-5472.CAN-05-2792, 16357189.
53. Rubin GL, Duong JH, Clyne CD, Speed CJ, Murata Y, Gong C, Simpson ER. Ligands of the peroxisomal proliferator-activated receptor gamma and the retinoid × receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose. Endocrinology 2002, 143:, 2863-2871.
54. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002, 18(suppl 2):S23-S29.
55. Sharma R, Sharma R, Verma U, Bhat NK. Novel drugs targeting retinoic acid receptors. JK Science 2005, 7:1-2.
56. Deb S, Zhou J, Amin SA, Imir AG, Yimaz MB, Lin Z, Bulun SE. A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I.3 and II by disrupting transcriptional complex in breast adipose fibroblasts. J Biol Chem 2006, 281:2585-2597.
57. Weidle UH, Grossmann A. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications of anticancer treatment. Anticancer Res 2000, 20:1471-1485.
58. Chen D, Reierstad S, Lin Z, Lu M, Brooks C, Li N, Innes J, Bulun SE. Prostaglandin E (2) induces breast cancer related aromatase promoters via activation of p38 and c-jun NH(2)-terminal kinase in adipose fibroblast. Cancer Res 2007, 67:8914-8922. 10.1158/0008-5472.CAN-06-4751, 17875734.
59. Gore SD, Carducci MA. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Investig drugs 2006, 15:721-727. 10.1517/13543784.15.6.721, 16732722.
60. Braddock M, Murray C. 10th anniversary inflammation and immune diseases Drug Discovery and Development Summit. 20-21 March 2006, New Brunswick, USA. Expert Opin Investig Drugs 2006, 15:721-727. 10.1517/13543784.15.6.721, 16732722.
61. Balunas MJ, Su B, Brueggemeier RW, Kinghorn AD. Natural products as aromatase inhibitors. Anticancer Agents Med Chem 2008, 8:646-682. 3074486, 18690828.
62. Daly JW. Marine toxins and nonmarine toxins: convergence or symbiotic organisms. J Nat Prod 2004, 67:1211-1215. 10.1021/np040016t, 15332834.
63. Cardy J, Walsh C. Lessons from natural molecules. Nature 2004, 432:829-837. 10.1038/nature03194, 15602548.
64. Butler MS. Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep 2008, 25:475-516. 10.1039/b514294f, 18497896.
65. Newman DJ, Cragg GM. Microbial antitumor drugs: natural products of microbial origin as anticancer agents. Curr Opin Investig Drugs 2009, 10:1280-1296.
66. Mayer AM, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, McIntosh JM, Newman DJ, Potts BC, Shuster DE. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci 2010, 31:255-265. 10.1016/j.tips.2010.02.005, 20363514.
67. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev 2009, 109:3012-3042. 10.1021/cr900019j, 19422222.
68. Eisenberg DM, Harris ES, Littlefield BA, Cao S, Craycroft JA, Scholten R, Bayliss P, Fu Y, Wang W, Qiao Y, Zhao Z, Chen H, Liu Y, Kaptchuk T, Hahn WC, Wang X, Roberts T, Shamu CE, Clardy J. Developing a library of authenticated Traditional Chinese medicinal (TCM) plants for systematic biological evaluation-rationale, methods and preliminary results from a Sino-American collaboration. Fitoterapia 2011, 82:17-33. 10.1016/j.fitote.2010.11.017, 21108995.
69. Basly JP, Lavier MC. Dietary phytoestrogens: potential selective estrogen enzyme modulators?. Planta Med 2005, 71:287-294. 10.1055/s-2005-864092, 15856402.
70. Edmunds KM, Holloway AC, Crankshaw DJ, Agarwal SK, Foster WG. The effects of dietary phytoestrogens on aromatase activity in human endometrial stromal cells. Reprod Nutr Dev 2005, 45:709-720. 10.1051/rnd:2005055, 16285913.
71. Whitehead SA, Lacey M. Phytoestrogens inhibit aromatase but not 17β-hydroxysteroid dehydrogenase (HSD) type 1 in human granulosa-luteal cells: evidence for FSH induction of 17β-HSD. Human Repro 2003, 18:487-494.
72. Rice S, Whitehead SA. Phytoestrogens and breast cancer-promoters or protectors?. Endocrine-Related Cancer 2006, 13:995-1015. 10.1677/erc.1.01159, 17158751.
73. Bal Z, Gust R. Breast cancer, estrogen receptor and ligands. Arch Pharm Chem Life Sci 2009, 342:133-149.
74. Adlercreutz H. Epidemiology of phytoestrogens. Bailliers Clin Endocrinol Metab 1998, 12:605-623.
75. Nichenametla SN, Taruscio TG, Barney DL, Exon JH. A review of the effects of mechanisms of polyphenolics in cancer. Crit Rev Food Sci Nutr 2006, 46:161-183. 10.1080/10408390591000541, 16431408.
76. Usui T. Pharmaceutical prospects of phytoestrogens. Endocrine J 2006, 53:7-20.
77. Mense SM, Hei TK, Ganju RK, Bhat HK. Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environ Health Persp 2008, 166:426-433.
78. Ursin G, Bernstein L, Pike MG. Breast cancer. Cancer Surv 1994, 19-20:241-264.
79. Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE. Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast cancer Res Treat 2003, 77:171-183. 10.1023/A:1021381101632, 12602916.
80. Kao YC, Zhou C, Sherman M, Laughton CA, Chen S. A site-directed mutagenesis study Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens. Environ Health Perspect 1998, 106:85-92. 1533268, 9539008.
81. Chen S, Zhang F, Sherman MA, Kijima I, Cho M, Yuan YC, Toma Y, Osawa Y, Zhou D, Eng ET. Structure-function studies of aromatase and its inhibitors: a progress report. J Steroid Biochem Mol Biol 2003, 86:231-237. 10.1016/S0960-0760(03)00361-3, 14623516.
82. Paoletta S, Steventon GB, Wildeboer D, Ehrman TM, Hylands PJ, Barlow DJ. Screening of herbal constituents for aromatase inhibitory activity. Bioorganic Med Chem 2008, 16:8466-8470.
83. Adam S, Chen S. Phytochemicals for breast cancer prevention by targeting aromatase. Front Biosci 2009, 14:3846-3863.
84. Zhao J, Dasmahapatra AK, Khan SI, Khan IA. Anti-aromatase activity of the constituents from damiana (Turnera diffusa). J Ethnopharmacol 2008, 120:387-393. 10.1016/j.jep.2008.09.016, 18948180.
85. Balunas MC, Kinghorn AD. Natural compounds with aromatase inhibitory activity: an update. Planta Med 2010, 76:1087-1093. 10.1055/s-0030-1250169, 2965731, 20635310.
86. Sanderson JT, Hordijk J, Denison MS, Springsteel MF, Nantz MH, van den Berg M. Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol Sci 2004, 82:70-79. 10.1093/toxsci/kfh257, 15319488.
87. Kijima I, Phung S, Hur G, Kwok SL, Chen S. Grape seed extract is an aromatase inhibitor and a suppressor of aromatase expression. Cancer Res 2006, (66):5960-5967.
88. Wang Y, Gho WM, Chan FL, Chen S, Leung LK. The red clover (trifolium pretense) isoflavone biochenin A inhibits aromatase activity and expression. Brit J Nutr 2008, 99:303-310.
89. Ye L, Chan MY, Leung LK. The soy isoflavone genistein induces estrogen synthesis in the extragonadal pathway. Mol Cell Endocrionol 2009, (302):73-80.
90. Ye L, Gho WM, Chan FL, Chen S, Leung LK. Dietary administration of the licorice flavonoid isoliquiritigenin deters the growth of MCF-7 cells overespressing aromatase. Int J can 2009, 124:1028-1036.
91. Wang Y, Lee KW, Chan FL, Chen S, Leung LK. The red wine polyphenol reseveratrol displays bilevel inhibition on aromatase in breast cancer cells. Toxicol Sci 2006, 92:71-77. 10.1093/toxsci/kfj190, 16611627.
92. Pope GS, Elcoate PV, Simpson SA, Andrews DG. Isolation of an oestrogenic isoflavone (biochanin A) from red clover. Chem Indus 1953, 1092.
93. Bennets HW, Underwood EJ, Shier FL. A specific breeding problem of sheep on subterranean clover pastures in western Australia. Aust Vet J 1946, 22:2-12. 10.1111/j.1751-0813.1946.tb15473.x, 21028682.
94. Linder HR. Occurrence of anabolic agents in plants and their importance. Environ Qual saf Suppl 1976, 5:151-158.
95. Kallela K, Heinonen K, saloniemi H. Plant oestrogens; the cause of decresed fertility in cows. A case report. Nord Vet Med 1984, 36:124-129.
96. Saloniemi H, Wahala K, Nykanen-Kurki P, Kallela K, Saastamoinen I. Phytoestrogen content and estrogenic effect of legume fodder. Proc Soc Exp Biol Med 1995, 208:13-17.
97. Almstrup K, Fernandez MF, Petersen JH, Olea N, Skakkebaek NE, Leffers H. Dual effects of phytoestrogens results in u-shaped dose-response curves. Environ Health perspect 2002, 110:743-748. 10.1289/ehp.02110743, 1240943, 12153753.
98. Franke AA, Custer LJ. High-performance liquid chromatographic assay of isoflavonoids and coumestrol from human urine. J chromatogram B Biomed Appl 1994, 662:47-60.
99. Mazur W, Fotsis T, Wahala K, Ojala S, Salakka A, Adlercreutz H. Isotope dilution gas chromatographic-mass spectrometric method for the determination of isoflavonoids, coumestrol, and lignans in food samples. Anal Biochem 1996, 233:169-180. 10.1006/abio.1996.0025, 8789715.
100. Nestel PJ, Yamashita T, sasahara T, Pomeroy S, Dart A, Komesaroff P, Owen A, Abbey M. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler thromb Vasc Biol 1997, 17:3392-3398. 10.1161/01.ATV.17.12.3392, 9437184.
101. Manonai J, Songchitsomboon S, Chanda K, Hong JH, Komindr S. The effect of a soy-rich diet on urogenital atrophy: a randomized, cross-over trial. Maturitas 2006, 54:135-140. 10.1016/j.maturitas.2005.09.011, 16297576.
102. Meeran SM, Ahmad A, Tollefsbol TO. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenetics 2010, 1:101-116. 10.1007/s13148-010-0011-5, 3024548, 21258631.
103. Barnes S. Effect of genistein on in vitro and in vivo model of cancer. J nutr 1995, 125:777s-783s.
104. Myllymaki S, Haavisto T, Vainio M, Toppari J, Paranko J. In vitro effects of diethylstilbestrol, genistein, 4-tert-butylphenol, and 4-tert-octylphenol on steroidogenic activity of isolated mature rat ovarian follicles. Toxicol Appl Pharmacol 2005, 204:69-80. 10.1016/j.taap.2004.08.009, 15781295.
105. Sanderson JT, Hordijk J, Denison MS, Springsteel MF, Nantz MH, van der Berg M. Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol Sci 2004, 82:70-79. 10.1093/toxsci/kfh257, 15319488.
106. Ju YH, Doerge DR, Woodling KA, Hartman JA, Kwak J, Helferich WG. Dietary genistein negates the inhibitory effect of latrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 2008, 29:2162-2168. 10.1093/carcin/bgn161, 2722859, 18632754.
107. Pelissero C, Lenczowski MJ, Chinzi D, Davail-Cuisset B, Sumpter JP, Fostier A. Eflavonoids on aromatase activity, an in vitro study. J steroid Biochem Mol boil 1996, 57:215-223.
108. Rice S, Mason HD, Whitehead SA. Phytoestrogens and their low dose combinations inhibit mRNA expression and activity of aromatase in human granulosa-luteal cells. J Steroid Biochem Mol Biol 2006, 101:216-225. 10.1016/j.jsbmb.2006.06.021, 16965912.
109. Kellis JT, Vickery LE. Inhibition of human estrogen synthase (aromatase) by flavones. Science 1984, 225:1032-1034. 10.1126/science.6474163, 6474163.
110. Wang C, Makela T, hase T, Kurzer MS. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J steroid Biochem Mol Biol 1994, 50:205-212. 10.1016/0960-0760(94)90030-2, 8049151.
111. van Meeuwen JA, Korthagen PC, de Jong PC, Piersma AH, van den Berg M. (Anti)estrogenic effects of phytochemicals on human primary mammary fibroblasts, MCF-7 cells and their co-culture. Toxicol appl Pharmacol 2007, 221:372-383. 10.1016/j.taap.2007.03.016, 17482226.
112. Prosperi JR, Robertson FM. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, p1.3, and pI.7 and estradiol production in human breast tumor cells. Prostaglandins Other Lipid Mediat 2006, 81:55-70. 10.1016/j.prostaglandins.2006.07.003, 16997132.
113. Brueggemeier RW, Su B, Darby MV, Sugimoto Y. Selective regulation of aromatase expression for drug discovery. J Steroid Biochem Mol Biol 2010, 118:207-210. 10.1016/j.jsbmb.2009.11.009, 19931613.
114. Knower KC, To SQ, Simpson ER, Clyne CD. Epigenetic mechanisms resulting CYP19 transcription in human breast adipose fibroblasts. Mol Cell Endocrinol 2010, 321:123-130. 10.1016/j.mce.2010.02.035, 20211687.
115. Fujii G, nakamura Y, Tsukamoto D, Ito M, Shiba T, Takamatsu N. CpG methylation at the USF-binding site is important for the liver-specific transcription of the chipmunk HP-27 gene. Biochem J 2006, 395:203-209. 10.1042/BJ20051802, 1409699, 16396632.
116. Jones B, Chen J. Inhibition of INF-gamma transcription by site-specific methylation during T helper cell development. EMBO J 2006, 25:2443-2452. 10.1038/sj.emboj.7601148, 1478170, 16724115.
117. Miyamoto K, Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jap J Clin Oncol 2005, 35:293-301.
118. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003, 63:7563-7570.
119. Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev 2004, 62:204-211. 10.1111/j.1753-4887.2004.tb00041.x, 15212320.
120. Krik H, Cefalu WT, Ribnicky D, Liu Z, Eilertsen KJ. Botanicals as epigenetic modulators for mechanisms contributing to development of metabolic syndrome. Metab Clinic Exp 2008, 57(suppl 1):S16-S23.